MedTrace Logo

Immunotherapy With Depigmented and Polymerized Allergen Extract of Phleum Pratense

NCT00501527 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2010-12-17

No results posted yet for this study

Summary

The objective of this trial is to evaluate the clinical effectiveness of the administration of a depigmented and polymerized allergen extract of Phleum pratense in the rhinoconjunctivitis and/or asthma of slight or moderate intensity, due to allergy to grass pollen.

Conditions

  • Rhinitis, Allergic, Seasonal
  • Conjunctivitis, Allergic
  • Asthma

Interventions

BIOLOGICAL

Immunotherapy with modified extract of P. pratense pollen

Sublingual (2 drops daily)

OTHER

Placebo

Placebo 2 drops daily

Sponsors & Collaborators

  • Laboratorios Leti, S.L.

    lead INDUSTRY

Principal Investigators

  • Félix Lorente, Prf. PhD

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2009-10-31
Completion
2009-10-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00501527 on ClinicalTrials.gov